These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35917100)

  • 1. Astragaloside IV in Hypoxic Pulmonary Hypertension: an In Vivo and In Vitro Experiments.
    XinTian ; Zhang X; Feng Y; Gao X; Hao X; Zhang J; Long Y; RongFang ; Zhang S; Li L
    Appl Biochem Biotechnol; 2022 Dec; 194(12):6319-6334. PubMed ID: 35917100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling.
    Jin H; Jiao Y; Guo L; Ma Y; Zhao R; Li X; Shen L; Zhou Z; Kim SC; Liu J
    Int J Mol Med; 2021 Feb; 47(2):595-606. PubMed ID: 33416126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response.
    Li C; Zhu H; Zhang S; Meng F; Li S; Li G; Zha J; Wu S; Zhu L; Dai A
    Phytomedicine; 2022 Jul; 102():154171. PubMed ID: 35636165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astragaloside IV attenuates hypoxia‑induced pulmonary vascular remodeling via the Notch signaling pathway.
    Yao J; Fang X; Zhang C; Yang Y; Wang D; Chen Q; Zhong G
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astragaloside IV alleviates lipopolysaccharide-induced preeclampsia-like phenotypes via suppressing the inflammatory responses.
    Tuerxun D; Aierken R; Zhang YM; Huang Y; Sui S; Li XY; Abulikemu Z; Dilixiati N
    Kaohsiung J Med Sci; 2021 Mar; 37(3):236-244. PubMed ID: 33089927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
    Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
    Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
    Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
    Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway.
    Liu Y; Tang BL; Lu ML; Wang HX
    J Cell Mol Med; 2023 Mar; 27(5):622-633. PubMed ID: 36762748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
    Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeic Acid Phenethyl Ester Rescues Pulmonary Arterial Hypertension through the Inhibition of AKT/ERK-Dependent PDGF/HIF-1α In Vitro and In Vivo.
    Cheng CC; Chi PL; Shen MC; Shu CW; Wann SR; Liu CP; Tseng CJ; Huang WC
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Chloro-DL-phenylalanine protects against monocrotaline‑induced pulmonary vascular remodeling and lung inflammation.
    Bai Y; Wang HM; Liu M; Wang Y; Lian GC; Zhang XH; Kang J; Wang HL
    Int J Mol Med; 2014 Feb; 33(2):373-82. PubMed ID: 24337018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
    Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
    Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia.
    Zhang T; Kawaguchi N; Yoshihara K; Hayama E; Furutani Y; Kawaguchi K; Tanaka T; Nakanishi T
    Respir Res; 2019 Apr; 20(1):79. PubMed ID: 31023308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response.
    Yang JM; Zhou R; Zhang M; Tan HR; Yu JQ
    Molecules; 2018 May; 23(6):. PubMed ID: 29861433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
    Huh JW; Kim SY; Lee JH; Lee YS
    Pulm Pharmacol Ther; 2011 Dec; 24(6):638-46. PubMed ID: 21963997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive and remedial application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension.
    Zhang LL; Lu J; Li MT; Wang Q; Zeng XF
    Int J Rheum Dis; 2016 Feb; 19(2):192-8. PubMed ID: 24612527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
    Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
    Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.
    Voelkel NF; Tuder RM; Bridges J; Arend WP
    Am J Respir Cell Mol Biol; 1994 Dec; 11(6):664-75. PubMed ID: 7946395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension.
    Sahara M; Sata M; Morita T; Hirata Y; Nagai R
    PLoS One; 2012; 7(3):e33367. PubMed ID: 22479390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
    Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
    BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.